BBS-Bioactive Bone Substitutes Plc | Company Release | November 29, 2024 at 16:20:00 EET
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc ("BBS", “the Company”) received a request on November 29, 2024, from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 60,000 of the convertible notes into Company shares at a conversion price of EUR 0.06111 per share. The conversion shall be carried out by transferring a total of 981,836 treasury shares to Riverfort.
The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.
After the transfers, Riverfort's entire loan capital has been converted into shares.
After the transfers, the Company will hold a total of 64,296 treasury shares in its possession.
.